Astellas Pharma, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3942400007
JPY
2,538.50
53 (2.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Net Sales
5,71,206.00
5,24,320.00
5,05,794.00
4,59,294.00
5,17,408.00
4,62,497.00
4,73,124.00
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
5,71,206.00
5,24,320.00
5,05,794.00
4,59,294.00
5,17,408.00
4,62,497.00
4,73,124.00
Raw Material Cost
1,49,129.00
1,38,252.00
1,27,596.00
1,09,419.00
1,33,493.00
1,16,928.00
1,26,128.00
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
2,446.00
2,693.00
5,898.00
3,907.00
4,227.00
5,048.00
4,495.00
Selling and Distribution Expenses
2,21,779.00
2,06,837.00
1,96,997.00
2,11,316.00
2,25,305.00
1,99,534.00
2,06,877.00
Other Expenses
7,314.90
6,889.80
6,580.00
7,232.20
7,486.50
8,046.10
8,232.60
Total Expenditure (Excl Depreciation)
4,46,503.00
4,16,680.00
3,96,291.00
3,96,964.00
4,37,890.00
4,01,971.00
4,19,826.00
Operating Profit (PBDIT) excl Other Income
124703
107640
109503
62330
79518
60526
53298
Other Income
11,746.00
-768.00
-11,595.00
1,768.00
-1,91,580.00
-16,452.00
-237.00
Operating Profit (PBDIT)
1,85,585.00
1,54,166.00
1,45,712.00
1,11,781.00
-60,898.00
94,091.00
1,03,329.00
Interest
2,446.00
2,693.00
5,898.00
3,907.00
4,227.00
5,048.00
4,495.00
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
4,22,077.00
3,86,068.00
3,78,198.00
3,49,875.00
3,83,915.00
3,45,569.00
3,46,996.00
Depreciation
49,136.00
47,294.00
47,804.00
47,683.00
51,164.00
50,017.00
50,268.00
Profit Before Tax
1,34,002.00
1,04,179.00
92,009.00
60,192.00
-1,16,290.00
39,028.00
48,566.00
Tax
33,634.00
24,977.00
21,994.00
-14,342.00
-20,699.00
2,639.00
12,892.00
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
1,00,323.00
79,213.00
68,422.00
74,896.00
-97,660.00
35,908.00
37,603.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
1,00,323.00
79,213.00
68,422.00
74,896.00
-97,660.00
35,908.00
37,603.00
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
1,00,323.00
79,213.00
68,422.00
74,896.00
-97,660.00
35,908.00
37,603.00
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
17,63,122.00
16,12,427.00
14,81,792.00
15,13,255.00
14,93,809.00
15,29,842.00
16,76,442.00
Earnings per share (EPS)
55.85
44.06
38.11
41.73
-54.55
19.97
20.94
Diluted Earnings per share
55.85
44.06
38.11
41.73
-54.55
19.97
20.94
Operating Profit Margin (Excl OI)
21.83%
20.53%
21.65%
13.57%
15.37%
13.09%
11.27%
Gross Profit Margin
32.06%
28.89%
27.64%
23.49%
-12.59%
19.25%
20.89%
PAT Margin
17.56%
15.11%
13.53%
16.31%
-18.87%
7.76%
7.95%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Dec 2025 is 10.40% vs 22.63% in Dec 2024

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Dec 2025 is 202.73% vs -772.91% in Dec 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Dec 2025 is 33.02% vs 50.74% in Dec 2024

stock-summary

Interest

YoY Growth in quarter ended Dec 2025 is -42.13% vs 49.36% in Dec 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024

Compare Quarterly Results Of Astellas Pharma, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(JPY)
Change(%)
Net Sales
5,71,206.00
11,91,698.00
-6,20,492.00
-52.07%
Other Operating Income
0.00
0.00
0.00
Total Operating income
5,71,206.00
11,91,698.00
-6,20,492.00
-52.07%
Raw Material Cost
1,49,129.00
5,43,062.00
-3,93,933.00
-72.54%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
2,446.00
1,23,627.00
-1,21,181.00
-98.02%
Selling and Distribution Expenses
2,21,779.00
2,82,783.00
-61,004.00
-21.57%
Other Expenses
7,314.90
5,160.40
2,154.50
41.75%
Total Expenditure (Excl Depreciation)
4,46,503.00
10,01,076.00
-5,54,573.00
-55.40%
Operating Profit (PBDIT) excl Other Income
1,24,703.00
190,622.00
-65,919.00
-34.58%
Other Income
11,746.00
66,071.00
-54,325.00
-82.22%
Operating Profit (PBDIT)
1,85,585.00
4,47,332.00
-2,61,747.00
-58.51%
Interest
2,446.00
1,23,627.00
-1,21,181.00
-98.02%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
4,22,077.00
6,48,636.00
-2,26,559.00
-34.93%
Depreciation
49,136.00
1,90,639.00
-1,41,503.00
-74.23%
Profit Before Tax
1,34,002.00
1,33,065.00
937.00
0.70%
Tax
33,634.00
30,131.00
3,503.00
11.63%
Provisions and contingencies
0
0
0.00
Profit After Tax
1,00,323.00
1,03,639.00
-3,316.00
-3.20%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
1,00,323.00
1,03,639.00
-3,316.00
-3.20%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
94.00
-94.00
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
1,00,323.00
1,03,733.00
-3,410.00
-3.29%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
17,63,122.00
76,42,943.00
-58,79,821.00
-76.93%
Earnings per share (EPS)
55.85
64.68
-8.83
-13.65%
Diluted Earnings per share
55.85
64.68
-8.83
-13.65%
Operating Profit Margin (Excl OI)
21.83%
16.00%
0.00
5.83%
Gross Profit Margin
32.06%
27.16%
0.00
4.90%
PAT Margin
17.56%
8.70%
0.00
8.86%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 57,120.60 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is 8.94% vs 3.66% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 10.40% vs 22.63% in Dec 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 10,032.30 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is 26.65% vs 15.77% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 202.73% vs -772.91% in Dec 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 17,383.90 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is 12.20% vs -1.51% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 33.02% vs 50.74% in Dec 2024

Quarterly - Interest
Interest 244.60 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is -9.17% vs -54.34% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is -42.13% vs 49.36% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 21.83%
in Dec 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024